ImvivaBio’s off-the-shelf CD19/BCMA CAR-T cell therapy CTA313 kept 88% of evaluable patients with refractory lupus in DORIS remission at Month 12, according to longer-term phase 1 data presented at ACR Convergence 2026.
|Articles|July 19, 2018
Novartis Has Production Hiccup for Kymriah CAR-T Therapy
Author(s)BioPharm International Editors
The company has run into a snag in producing Kymriah for the diffuse large B-cell lymphoma patient population, the second indication for which the therapy was recently approved by FDA.
Advertisement
In its second quarter 2018 earnings call held on July 18, 2018, Novartis executives discussed a production issue that the company has encountered for its chimeric antigen receptor T-cell (CAR-T) therapy, Kymriah (tisagenlecleucel), when producing the therapy to treat diffuse large B-cell lymphoma (DLBCL). FDA granted Kymriah approval for this
The production glitch centers around the variability in product specification for the therapy; the product does not meet commercial specifications in the DLBCL indication at this time. This is due to the fact that the CAR-T therapy is manufactured individually for each patient using the patient's own T cells, as stated by Novartis.
“On manufacturing, we have seen some variability in our product specifications. This is something we’re looking at now in DLBCL to make sure that we can continue to ramp up the demand. We feel confident in the overall longer-term outlook for Kymriah,” said Vas Narasimhan, CEO, Novartis, in the second-quarter earnings call.
“The variability that we’ve seen in the commercial specifications, which isn’t unusual with a new therapy as you launch it into a new target patient population, is that we have still been able to deliver final product to the majority of patients. It is really more of a specification [issue], and we’re working directly with FDA on trying to solve the issue as well as looking at new ways to improve our output to meet more commercial specification on Kymriah,” added Liz Barrett, CEO, Novartis Oncology, in the earnings call.
In an emailed statement issued by Novartis, the company said:
“Since the FDA approval of Kymriah in August 2017, Novartis has been delivering treatment for pediatric and young adult acute lymphoblastic leukemia (ALL) patients with a high level of success. With the recent introduction of the diffuse large B-cell lymphoma (DLBCL) indication, we have identified variability in meeting final product commercial specifications in DLBCL and are working to resolve this as soon as possible. Our priority goal is to provide this transformative product to patients in both indications, and we have been able to deliver Kymriah to the majority of our patients.
Novartis is committed to sharing this information with treating physicians, so they can make the best decision with their patients. For cases where the product does not meet commercial specifications, we have developed an Expanded Access Program path to deliver treatment, when possible.
We are committed to resolving this as quickly as possible and to serving all patients who may be able to benefit from this transformative therapy.”
Source:
Advertisement
Related to this article
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Full phase 3 OASIZ-301 results show both dosing regimens of Amgen’s CD40L antagonist fusion protein dazodalibep reduced systemic disease activity in Sjögren’s disease at Week 48. The every-four-weeks dose also improved patient-reported dryness.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5